Goetz and Choong Describe the Need for Adjuvant Endocrine Therapy in ER-positive Breast Cancer


In Partnership With:

Drs Goetz and Choong discuss the potential for adjuvant endocrine therapy omission in patients with estrogen receptor–positive breast cancer who have a pathologic complete response to neoadjuvant chemotherapy.

Welcome to OncLive On Air®! I’m your host today, Ashling Wahner.

OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with Matthew P. Goetz, MD, and Grace Choong, MD, on research they presented at the 2022 San Antonio Breast Cancer Symposium. Goetz is a consultant in the Division of Medical Oncology in the Department of Oncology, as well as a professor of oncology and a professor of pharmacology at Mayo Clinic in Rochester, Minnesota. Choong is a hematology/oncology fellow at Mayo Clinic.

In our exclusive interview, Drs Goetz and Choong discussed the potential for adjuvant endocrine therapy omission in patients with estrogen receptor (ER)–positive breast cancer who have a pathologic complete response to neoadjuvant chemotherapy, how far the breast cancer treatment landscape has come in the past few decades, and how this research confirms the importance of adjuvant endocrine therapy in patients with ER-positive breast cancer with residual disease.


That’s all we have for today! Thank you for listening to this episode of OncLive On Air®. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air®.

*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Related Videos
Ko Un “Clara” Park, MD
Erin Frances Cobain, MD
Matthew P. Goetz, MD
Video 3 - "5-Year Data from the MonarchE Trial Investigating Abemaciclib in HR+, HER2- High-Risk, Early Breast Cancer"
Saad J. Kenderian, MB, CHB
Carlos Arteaga, MD
Video 2 - "NCCN Guidelines vs Real-World Practice: Risk Stratifying HR+/HER2- Early Breast Cancer"
Reshma L. Mahtani, DO
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic